IVIG Identified as a Treatment Marker of High Medical Costs, Resource Utilization in Patients With Myasthenia Gravis
Often used as a treatment for severe exacerbations of myasthenia gravis, intravenous immunoglobulin can lead to high financial toxicity and resource utilization.